Illicit use of opioid substitution drugs: Prevalence, user characteristics, and the association with non-fatal overdoses

Drug and Alcohol Dependence

Volumn 147, Issue , 2015, Pages 89-96

  Bretteville Jensen, Anne Line ^a   Lillehagen, Mats ^a   Gjersing, Linn ^a   Andreas, Jasmina Burdzovic ^a  

^a NORWEGIAN INSTITUTE FOR ALCOHOL AND DRUG RESEARCH   (Norway)

Author keywords

Buprenorphine; Diversion; Injecting drug users; Methadone; Opioid substitution treatment

Indexed keywords

AMPHETAMINE; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CENTRAL STIMULANT AGENT; COCAINE; DIAMORPHINE; ILLICIT DRUG; METHADONE; OPIATE; STREET DRUG;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG OVERDOSE; EDUCATION; FEMALE; HIGH RISK POPULATION; HOMELESSNESS; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NORWAY; OPIATE SUBSTITUTION TREATMENT; PRESCRIPTION DRUG DIVERSION; PREVALENCE; RISK FACTOR; ADVERSE EFFECTS; DRUG USE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PROCEDURES; YOUNG ADULT;

ADULT; BUPRENORPHINE; CROSS-SECTIONAL STUDIES; DRUG OVERDOSE; DRUG USERS; FEMALE; HEROIN; HUMANS; MALE; METHADONE; MIDDLE AGED; NORWAY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREVALENCE; RISK FACTORS; STREET DRUGS; YOUNG ADULT;

EID: 84920973640     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.12.002     Document Type: Article

References (54)

1. Alho H., Sinclair D., Vuori E., Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007, 88:75-78.
2. Bazazi A.R., Yokell M., Fu J.J., Rich J.D., Zaller N.D. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J. Addict. Med. 2011, 5:175.
3. Bernard J.P., Havnes I., Slordal L., Waal H., Morland J., Khiabani H.Z. Methadone-related deaths in Norway. Forensic Sci. Int. Genet. 2013, 224:111-116.
4. Bretteville-Jensen A.L. Drug demand - initiation continuation and quitting,. De Economist 2006, 154(4):491-516.
5. Cameron A.C., Trivedi P.K. Microeconometrics: Methods and Applications 2005, Cambridge University Press, Cambridge.
6. Clausen T., Anchersen K., Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008, 94:151-157.
7. Daniulaityte R., Falck R., Carlson R.G. Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids. Drug Alcohol Depend. 2012, 122:201-207.
8. Darke S., Mattick R.P., Degenhardt L. The ratio of non-fatal to fatal heroin overdose. Addiction 2003, 98:1169-1171.
9. Darke S., Mills K.L., Ross J., Teesson M. Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001-2009. Drug Alcohol Depend. 2011, 115:190-195.
10. Darke S., Ross J., Hall W. Overdose among heroin users in Sydney, Australia. 1. Prevalence and correlates of non-fatal overdose. Addiction 1996, 91:405-411.
11. Darke S., Topp L., Ross J. The injection of methadone and benzodiazepines among Sydney injecting drug users 1996-2000: 5-year monitoring of trends from the Illicit Drug Reporting System. Drug Alcohol Rev. 2002, 21:27-32.
12. Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M., McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011, 106:32-51.
13. Degenhardt L., Randall D., Hall W., Law M., Butler T., Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009, 105:9-15.
14. Duffy P., Baldwin H. The nature of methadone diversion in England: a Merseyside case study. Harm. Reduct. J. 2012, 9:1-10.
15. EMCDDA European Drug Report 2013 2013, EMCDDA, Lisbon, Portugal.
16. Ernst E., Bartu A., Popescu A., Ilett K.F., Hansson R., Plumley N. Methadone-related deaths in Western Australia 1993-99. Aust. N.Z. J. Public Health 2002, 26:364-370.
17. Ferrant O. Fatal poisoning due to snorting buprenorphine and alcohol consumption. Forensic Sci. Int. Genet. 2011, 204:e8-e11.
18. Genberg B.L., Gillespie M., Schuster C.R., Johanson C.-E., Astemborski J., Kirk G.D., Vlahov D., Mehta S.H. Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. Addict. Behav. 2013, 38:2868-2873.
19. Gjersing L., Bretteville-Jensen A.L. Is opioid substitution treatment beneficial if injecting behaviour continues?. Drug Alcohol Depend. 2013, 133:121-126.
20. Harris M., Rhodes T. Methadone diversion as a protective strategy: the harm reduction potential of 'generous constraints'. Int. J. Drug Policy 2013, 24:e43-e50.
21. Heinemann A., Iwersen-Bergmann S., Stein S., Schmoldt A., Püschel K. Methadone-related fatalities in Hamburg 1990-1999: implications for quality standards in maintenance treatment?. Forensic Sci. Int. Genet. 2000, 113:449-455.
22. Hordvin O.(red) The Drug Situation in Norway 2013. Annual Report to the EMCDDA 2013, SIRUS, Oslo.
23. Häkkinen M., Launiainen T., Vuori E., Ojanperä I. Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. Eur. J. Clin. Pharmacol. 2012, 68:301-309.
24. Ison J., Day E., Fisher K., Pratt M., Hull M., Copello A. Self-detoxification from opioid drugs. J. Subst. Use 2006, 11:81-88.
25. Jenkinson R.A., Clark N.C., Fry C.L., Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?. Addiction 2005, 100:197-205.
26. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci. Int. Genet. 2001, 121:65-69.
27. Lai S.H., Yao Y.J., Lo D.S.T. A survey of buprenorphine related deaths in Singapore. Forensic Sci. Int. Genet. 2006, 162:80-86.
28. Lee S., Klein-Schwartz W., Welsh C., Doyon S. Medical outcomes associated with nonmedical use of methadone and buprenorphine. J. Emerg. Med. 2013, 45:199-205.
29. McCance-Katz E.F., Sullivan L.E., Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am. J. Addict. 2010, 19:4-16.
30. Mégarbane B., Hreiche R., Pirnay S., Marie N., Baud F.J. Does high-dose buprenorphine cause respiratory depression?. Toxicol. Rev. 2006, 25:79-85.
31. Mitchell S.G., Kelly S.M., Brown B.S., Reisinger H.S., Peterson J.A., Ruhf A., Agar M.H., O'Grady K.E., Schwartz R.P. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am. J. Addict. 2009, 18:346-355.
32. Nielsen S., Dietze P., Cantwell K., Lee N., Taylor D. Methadone- and buprenorphine-related ambulance attendances: a population-based indicator of adverse events. J. Subst. Abuse Treat. 2008, 35:457-461.
33. Nielsen S., Dietze P., Lee N., Dunlop A., Taylor D. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction 2007, 102:616-622.
34. Obadia Y., Perrin V., Feroni I., Vlahov D., Moatti J.P. Injecting misuse of buprenorphine among French drug users. Addiction 2001, 96:267-272.
35. Ompad D.C., Fuller C.M., Chan C.A., Frye V., Vlahov D., Galea S. Correlates of illicit methadone use in New York City: a cross-sectional study. BMC Public Health 2008, 8:375.
36. Otiashvili D., Zabransky T., Kirtadze I., Piralishvili G., Chavchanidze M., Miovsky M. Why do the clients of Georgian needle exchange programmes inject buprenorphine?. Eur. Addict. Res. 2010, 16:1-8.
37. Pani P.P., Pirastu R., Ricci A., Gessa G.L. Prohibition of take-home dosages: negative consequences on methadone maintenance treatment. Drug Alcohol Depend. 1996, 41:81-84.
38. Pirnay S., Borron S., Giudicelli C., Tourneau J., Baud F., Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004, 99:978-988.
39. Renard D., Gaillard N. Brain haemorrhage and cerebral vasospasm associated with chronic use of cannabis and buprenorphine. Cerebrovasc. Dis. 2008, 25:282-283.
40. Riksheim M., Gossop M., Clausen T. From methadone to buprenorphine: changes during a 10year period within a national opioid maintenance treatment programme. Subst. Abuse Treat. 2014, 46:291-294.
41. Ritter A., Ritter A., Di Natale R. The relationship between take-away methadone policies and methadone diversion. Drug Alcohol Rev. 2005, 24:347-352.
42. Roche A., McCabe S., Smyth B.P. Illicit Methadone use and abuse in young people accessing treatment for opiate dependence. Eur. Addict. Res. 2008, 14:219-225.
43. Schifano F., Corkery J., Gilvarry E., Deluca P., Oyefeso A., Ghodse A.H. Buprenorphine mortality, seizures and prescription data in the UK, 1980-2002. Hum. Psychopharmacol. 2005, 20:343-348.
44. Seldén T., Ahlner J., Druid H., Kronstrand R. Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. Forensic Sci. Int. Genet. 2012, 220:284-290.
45. Seymour A., Black M., Jay J., Cooper G., Weir C., Oliver J. The role of methadone in drug-related deaths in the west of Scotland. Addiction 2003, 98:995-1002.
46. Skretting A., Lund K.E., Bye E.K. Rusmidler i Norge 2013 2014, SIRUS, Oslo, Norway.
47. Stoove M.A., Dietze P.M., Jolley D. Overdose deaths following previous non-fatal heroin overdose: record linkage of ambulance attendance and death registry data. Drug Alcohol Rev. 2009, 28:347-352.
48. Strang J., Hall W., Hickman M., Bird S.M. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. BMJ 2010, 341. 10.1136/bmj.c4851.
49. The Norwegian Pharmaceutical Product Compendium. (accessed 01.10.14). http://www.felleskatalogen.no/.
50. Tracqui A., Kintz P., Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J. Anal. Toxicol. 1998, 22:430-434.
51. Vlahov D., O'driscoll P., Mehta S., Ompad D., Gern R., Galai N., Kirk G. Risk factors for methadone outside treatment programs: implications for HIV treatment among injection drug users. Addiction 2007, 102:771-777.
52. Vormfelde S.V., Poser W. Death attributed to methadone. Pharmacopsychiatry 2001, 34:217-222.
53. Waal H. Merits and problems in high-threshold methadone maintenance treatment. Evaluation of medication-assisted rehabilitation in Norway 1998-2004. Eur. Addict. Res. 2007, 13:66-73.
54. Winstock A.R., Lea T., Sheridan J. What is diversion of supervised buprenorphine and how common is it?. J. Addict. Dis. 2009, 28:269-278.